KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

  • Rapidly Growing, Globally Positioned Biopharmaceutical Company
    - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics
     
  • Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder
    - Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity
     
  • Significant Opportunity in Novel Inhaled AAT Undergoing Pivotal Clinical Development
     
  • Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma
     
  • Valuable R&D Pipeline Focused on Various Orphan Indications
     
  • Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How
     
  • Strong Financial Profile with Increasing Profitability

LATEST NEWS

Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Feb. 21, 2017

The conpany announced today a collaboration with Massachusetts General Hospital (MGH) to conduct a proof of concept study evaluating the potential benefit of the Company’s Liquid Alpha-1 Antitrypsin (AAT) on liver preservation.

Kamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors

Feb. 8, 2017

Kamada announced today the appointment of Gwen A. Melincoff to the Company’s Board of Directors.

More News

FINANCIAL REPORTS

Q2 / 2016 Financial Report

Aug. 3, 2016

Q1 / 2016 Financial Report

May. 9, 2016

Annual report 2015

Dec. 31, 2015

More Reports

STOCK QUOTE

NASDAQ

KMDA:$7.1
Change:0.71%
Date & Time:2/21/2017 3:44pm
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Gil Efron
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more